Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I tolerability and pharmacokinetics study of inhaled isoniazid in tuberculosis
NL-OMON56472Phase 1Not yet recruiting
- Sponsor
- University of Groningen
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isoniazid in Tuberculosis (TB), sponsored by University of Groningen. Primary endpoint: Local tolerability. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON56472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56472.